Article
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology - 1 Oct 2013
Marcellin Patrick, Cooper Curtis, Balart Luis, Larrey Dominique, Box Terry, Yoshida Eric, Lawitz Eric, Buggisch Peter, Ferenci Peter, Weltman Martin, Labriola-Tompkins Emily, Le Pogam Sophie, Nájera Isabel, Thomas Denise, Hooper Gregory, Shulman Nancy S, Zhang Ying, Navarro Mercidita T, Lim Chin Yin, Brunda Michael, Terrault Norah A, Yetzer Ellen S
Abstract excerpt
BACKGROUND & AIMS: The combination of a hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for patients with HCV genotype 1 infection. We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients. METHODS: Treatment-naïve patients (N = 237)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.